Evidence map›Paper›PMID 35687207›Full record

Observational studyMedical oncology (Northwood, London, England)2022

Prospective assessment of AR splice variant and multi-biomarker expression on circulating tumor cells of mCRPC patients undergoing androgen receptor targeted agents: interim analysis of PRIMERA trial (NCT04188275).

Giulio Francolini, Mauro Loi, Lucia Pia Ciccone, Beatrice Detti, Vanessa Di Cataldo, Pamela Pinzani, Francesca Salvianti, Giulia Salvatore, Mariangela Sottili, Costanza Santini and 13 more

Open access · greenAbstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in Medical oncology (Northwood, London, England), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 2 institutions in 1 country.

Giulio Francolini *Radiation Oncology Unit, Azienda Ospedaliero-Universitaria Careggi, Viale Morgagni 85, 50134, Florence, Italy. francolinigiulio@gmail.com.ORCID http://orcid.org/0000-0002-1784-7203
Mauro Loi *Radiation Oncology Unit, Azienda Ospedaliero-Universitaria Careggi, Viale Morgagni 85, 50134, Florence, Italy.
Lucia Pia CicconeDepartment of Biomedical, Experimental, and Clinical Sciences "Mario Serio", University of Florence, Florence, Italy.
Beatrice DettiRadiation Oncology Unit, Azienda Ospedaliero-Universitaria Careggi, Viale Morgagni 85, 50134, Florence, Italy.
Vanessa Di CataldoRadiation Oncology Unit, Azienda Ospedaliero-Universitaria Careggi, Viale Morgagni 85, 50134, Florence, Italy.
Pamela PinzaniDepartment of Biomedical, Experimental, and Clinical Sciences "Mario Serio", University of Florence, Florence, Italy.
Francesca SalviantiDepartment of Biomedical, Experimental, and Clinical Sciences "Mario Serio", University of Florence, Florence, Italy.
Giulia SalvatoreDepartment of Biomedical, Experimental, and Clinical Sciences "Mario Serio", University of Florence, Florence, Italy.
Mariangela SottiliDepartment of Biomedical, Experimental, and Clinical Sciences "Mario Serio", University of Florence, Florence, Italy.
Costanza SantiniDepartment of Biomedical, Experimental, and Clinical Sciences "Mario Serio", University of Florence, Florence, Italy.
Giulio FrosiniDepartment of Biomedical, Experimental, and Clinical Sciences "Mario Serio", University of Florence, Florence, Italy.
Luca VisaniRadiation Oncology Unit, Azienda Ospedaliero-Universitaria Careggi, Viale Morgagni 85, 50134, Florence, Italy.
Luca BurchiniDepartment of Biomedical, Experimental, and Clinical Sciences "Mario Serio", University of Florence, Florence, Italy.
Chiara MattioliDepartment of Biomedical, Experimental, and Clinical Sciences "Mario Serio", University of Florence, Florence, Italy.
Andrea Gaetano AllegraDepartment of Biomedical, Experimental, and Clinical Sciences "Mario Serio", University of Florence, Florence, Italy.
Marianna ValzanoDepartment of Biomedical, Experimental, and Clinical Sciences "Mario Serio", University of Florence, Florence, Italy.
Cecilia CerbaiDepartment of Biomedical, Experimental, and Clinical Sciences "Mario Serio", University of Florence, Florence, Italy.
Michele AquilanoDepartment of Biomedical, Experimental, and Clinical Sciences "Mario Serio", University of Florence, Florence, Italy.
Viola SalvestriniDepartment of Biomedical, Experimental, and Clinical Sciences "Mario Serio", University of Florence, Florence, Italy.
Isacco DesideriDepartment of Biomedical, Experimental, and Clinical Sciences "Mario Serio", University of Florence, Florence, Italy.
Monica MangoniRadiation Oncology Unit, Azienda Ospedaliero-Universitaria Careggi, Viale Morgagni 85, 50134, Florence, Italy.
Icro MeattiniRadiation Oncology Unit, Azienda Ospedaliero-Universitaria Careggi, Viale Morgagni 85, 50134, Florence, Italy.
Lorenzo LiviRadiation Oncology Unit, Azienda Ospedaliero-Universitaria Careggi, Viale Morgagni 85, 50134, Florence, Italy.
University of Florence · ITAzienda Ospedaliero-Universitaria Careggi · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Circulating tumor cells detection and ARV7 expression are associated with worse clinical outcomes in metastatic Castration-Resistant Prostate Cancer (mCRPC) undergoing Androgen Receptor Targeted Agents. ARFL, PSMA and PSA may help to refine prognostic models. In our institution, a prospective observational trial testing CTC detection in mCPRC undergoing I line ARTA therapy terminated the planned enrollment in 2020. Here, we present a pre-planned interim analysis with 18 months of median follow-up. RT-qPCR was used to determine the CTC expression of PSA, PSMA, AR and ARV7 before starting ARTA. PSA-drop, Progression-Free and Overall Survival (PFS and OS) and their correlation with CTC detection were reported. Forty-four patients were included. CTC were detected in 43.2% of patients, of whom 8.94% expressed PSA, 15.78% showed ARV7, 63.15% and 73.68% displayed ARFL and PSMA, respectively. Biochemical response was significantly improved in CTC + vs CTC- patients, with median PSA-drop of 18.5 vs 2.5 ng/ml (p = 0.03). After a median follow-up of 18 months, 50% of patients progressed. PFS was significantly longer in CTC- patients (NR vs 16 months). Eight (18.2%) patients died, a non-significant trend in terms of OS was detected in favor of CTC- patients (NR vs 29 months, p = 0.05). AR, PSA and PSMA expression in CTC + had no significant impact on PSA-drop, PFS or OS. PRIMERA-trial confirmed the CTC detection predictive importance in mCRPC patients.

Indexed as

Antineoplastic AgentsNeoplastic Cells, CirculatingProstatic Neoplasms, Castration-ResistantBiomarkers, TumorHumansMaleProspective StudiesProstate-Specific AntigenReceptors, AndrogenTreatment OutcomeAntineoplastic AgentsBiomarkers, TumorProstate-Specific AntigenReceptors, AndrogenAR splice variantsBiomarkerCTCsMetastatic castration-resistant prostate cancerPSMA

Identifiers

PMID35687207
OpenAlexW4281979092

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.